Active Ingredient History
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Acute Coronary Syndrome (Phase 4)
Acute Disease (Phase 3)
Anemia, Sickle Cell (Phase 2)
Angina Pectoris (Phase 2)
Angioplasty (Phase 4)
Angioplasty, Balloon, Coronary (Phase 3)
Arterial Occlusive Diseases (Phase 2/Phase 3)
Brain Ischemia (Phase 3)
Carotid Stenosis (Phase 1/Phase 2)
Constriction, Pathologic (Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Diabetes Mellitus (Phase 4)
Hemoglobins (Phase 2)
Infarction, Middle Cerebral Artery (Phase 4)
Ischemia (Phase 4)
Myocardial Infarction (Phase 4)
Pain (Phase 2)
Shock, Cardiogenic (Phase 4)
ST Elevation Myocardial Infarction (Phase 4)
Stroke (Phase 3)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue